Avalo Therapeutics(us:AVTX)
8.91
-1.87%
Updated on 2024-12-22
Open:9.10
Close:8.91
High:9.81
Low:8.67
Pre Close:9.08
Volume:949861.00
Amount:8.54M
Turnover:9.06%
Shares:10.49M
MarketCap:93.45M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 24 | 232023 | 22.44% | 6 | 4 | 8 |
| 2024-03-31 | 20 | 87507 | 8.46% | 8 | 3 | 6 |
| 2023-12-31 | 28 | 22966 | 2.86% | 4 | 5 | 16 |
| 2023-09-30 | 35 | 5661 | 0.00% | 10 | 4 | 13 |
| 2023-06-30 | 36 | 2427693 | 17.30% | 4 | 7 | 15 |
| 2023-03-31 | 36 | 9131084 | 69.17% | 8 | 9 | 11 |
| 2022-12-31 | 30 | 5551066 | 58.86% | 3 | 4 | 10 |
| 2022-09-30 | 55 | 5550139 | 58.96% | 4 | 6 | 41 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Ikarian Capital, Llc | 46648 | 4.51% | 46648 | |
| 2024-03-31 | Sio Capital Management, Llc | 10151 | 0.98% | 10151 | |
| 2024-03-31 | Affinity Asset Advisors, Llc | 10000 | 0.97% | 10000 | |
| 2024-03-31 | Ubs Group Ag | 7713 | 0.75% | 7711 | 385550.00% |
| 2024-03-31 | Adar1 Capital Management, Llc | 6000 | 0.58% | 6000 | |
| 2024-03-31 | Natixis | 2512 | 0.24% | -2092 | -45.44% |
| 2024-03-31 | Blackrock Inc. | 2124 | 0.21% | -13752 | -86.62% |
| 2024-03-31 | Tower Research Capital Llc (Trc) | 1640 | 0.16% | -126 | -7.13% |
| 2024-03-31 | Banque Cantonale Vaudoise | 338 | 0.03% | 338 | |
| 2024-03-31 | Royal Bank Of Canada | 322 | 0.03% | 184 | 133.33% |
About
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Address:540 Gaither Road,Suite 400
Website:http://www.cerecor.com
Market Movers